Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (851-860 of 968) with videos related to

Pageof 97
Sort By:
Blood Cancer Journal|August 30, 2020
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myelomaAshley Paquin, Alissa Visram, Shaji K Kumar, et al.
Leukemia|November 30, 2019
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological featuresSurbhi Sidana, Daniel P Larson, Patricia T Greipp, et al.
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Pageof 97

Showing results (851-860 of 968) with videos related to

Sort By:
Pageof 97
Blood Cancer Journal|August 30, 2020
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myelomaAshley Paquin, Alissa Visram, Shaji K Kumar, et al.
Leukemia|November 30, 2019
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological featuresSurbhi Sidana, Daniel P Larson, Patricia T Greipp, et al.
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Pageof 97